Patient-reported oral adverse events during cancer chemotherapy: longitudinal evaluation using patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) and concordance with clinician assessments
Supportive Care in Cancer · 2025
DOI: 10.1007/s00520-025-10126-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Supportive Care in Cancer, 2025. Verfasst von Yuki Sakai und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Niigata University Medical and Dental Hospital, 1-754 Asahimachi-Dori Chuoh-Ku, Niigata, 951-8520, Japan. yu-yu117@med.niigat…. Hauptthemen laut MEDLINE: Patient Reported Outcome Measures, Neoplasms, Antineoplastic Agents, Stomatitis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Patientensicherheit, Onkologische Pflege
Abstract (Originalsprache)
Purpose
This study aimed to (1) describe longitudinal trends in patient-reported oral adverse events using the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) in patients receiving multidisciplinary oral care during outpatient cancer drug therapy, and (2) evaluate concordance between PRO-CTCAE and clinician-reported CTCAE scores.
Methods
Conducted at the Outpatient Cancer Chemotherapy Center, Niigata University Medical and Dental Hospital (June–December 2023), oral adverse events were assessed using PRO-CTCAE and CTCAE at baseline and every 3 weeks up to 24 weeks. Concordance for dry mouth and oral mucositis was evaluated using paired same-day scores.
Results
Among patients receiving multidisciplinary oral care, 85.2% experienced at least one oral adverse event, most commonly dry mouth. Based on PRO-CTCAE, symptoms rated as moderate or higher were reported in fewer than 10% of cases for most items. Notably, over half of patients reported persistent dry mouth of at least mild severity, and 20–30% of other symptoms also remained. These findings suggest that even lower-grade symptoms may persist and affect quality of life. Concordance between PRO-CTCAE and CTCAE was limited, with 31.1% of patients reporting greater dry mouth severity than clinicians documented.
Conclusions
Patient-reported oral adverse events, as assessed by PRO-CTCAE, were frequently mild but persistent throughout outpatient chemotherapy, suggesting a cumulative impact on quality of life. Concordance between PRO-CTCAE and clinician-reported CTCAE was limited, indicating that clinician assessments may underestimate symptoms such as dry mouth. These findings underscore the need to integrate patient-reported outcomes into routine oral care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Niigata University Medical and Dental Hospital, 1-754 Asahimachi-Dori Chuoh-Ku, Niigata, 951-8520, Japan. yu-yu117@med.niigata-u.ac.jp.
- Department of Outpatient Cancer Chemotherapy Center, Niigata University Medical and Dental Hospital, Niigata, Japan. yu-yu117@med.niigata-u.ac.jp.
- Department of Oral Radiology, Niigata University Medical and Dental Hospital, Niigata, Japan.
- Department of Pharmacy, Niigata University Medical and Dental Hospital, 1-754 Asahimachi-Dori Chuoh-Ku, Niigata, 951-8520, Japan.
- Department of Outpatient Cancer Chemotherapy Center, Niigata University Medical and Dental Hospital, Niigata, Japan.
Zitieren
APA
Sakai, Y., Katsura, K., Kanemitsu, Y., Kotake, M., & Toyama, A. (2025). Patient-reported oral adverse events during cancer chemotherapy: longitudinal evaluation using patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) and concordance with clinician assessments. Supportive Care in Cancer. https://doi.org/10.1007/s00520-025-10126-3
Vancouver
Sakai Y, Katsura K, Kanemitsu Y, Kotake M, Toyama A. Patient-reported oral adverse events during cancer chemotherapy: longitudinal evaluation using patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) and concordance with clinician assessments. Supportive Care in Cancer. 2025. doi:10.1007/s00520-025-10126-3
BibTeX
@article{Sakai2025,
author = {Sakai, Yuki and Katsura, Kouji and Kanemitsu, Yoshitomi and Kotake, Masaaki and Toyama, Akira},
title = {Patient-reported oral adverse events during cancer chemotherapy: longitudinal evaluation using patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) and concordance with clinician assessments},
journal = {Supportive Care in Cancer},
year = {2025},
doi = {10.1007/s00520-025-10126-3}
}
EUVIMED